CAS: 875337-44-3 - N-[(3-fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide
Formula:C26H20FN5O2S2
InChI:InChI=1/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35)
- Synonyms:
- Mgcd-265
N-[[[3-Fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]benzeneacetamide
CAS:875337-44-3
Formula:
C26H20FN5O2S2
Purity:
98+%
Color and Shape:
Solid
Molecular weight:
517.5977
Ref: AN-AG003AKW
10mg | 152.00 € | |
25mg | 183.00 € | |
50mg | 292.00 € | |
100mg | 619.00 € |
Estimated delivery in United States, on Wednesday 8 May 2024
MGCD-265 analog
CAS:875337-44-3
MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity …
Formula:
C26H20FN5O2S2
Purity:
99.21%
Color and Shape:
Solid
Molecular weight:
517.6
Ref: TM-T6351
1mg | 55.00 € | |
2mg | 77.00 € | |
5mg | 112.00 € | |
10mg | 195.00 € | |
25mg | 324.00 € | |
50mg | 482.00 € | |
100mg | 700.00 € | |
1ml*10 (DMSO) | 138.00 € |
Estimated delivery in United States, on Wednesday 15 May 2024
MGCD 265
CAS:875337-44-3
Inhibits MET, VEGFR1-3, Tie and Ron tyrosine kinases; antineoplastic
Formula:
C26H20FN5O2S2
Purity:
Min. 95%
Molecular weight:
517.10425
Ref: 3D-FF41064
2mg | 66.00 € | |
5mg | 103.00 € | |
10mg | 147.00 € | |
25mg | 264.00 € | |
50mg | 372.00 € |
Estimated delivery in United States, on Friday 31 May 2024
Ref: TR-M198700
250mg | 5,356.00 € |
Estimated delivery in United States, on Tuesday 18 Jun 2024